Schonfeld Strategic Advisors LLC purchased a new position in Global Cord Blood Co. (NYSE: CO) during the third quarter, Channel.com Holdings reports. The fund bought 39,900 shares of the medical research firm, valued at approximately $ 142,000.
Separately, Arrowstreet Capital Limited Partnership raised its position in Global Cord Blood shares by 89.1% during the third quarter. Arrowstreet Capital Limited Partnership now owns 432,759 shares of the medical research firm valued at $ 1,532,000 following the purchase of 203,965 additional shares in the last quarter.
Actions of CO opened at $ 3.71 on Friday. The company’s 50-day moving average is $ 3.89 and its 200-day moving average is $ 3.59. The company has a market capitalization of $ 450.95 million, a PE index of 6.29 and a beta of 0.41. Global Cord Blood Co. saw a $ 2.54 decline in 12 months and a $ 5.25 rise in 12 months.
Global Cord Blood (NYSE: CO) last released its earnings results on Tuesday, November 24th. The medical research company reported $ 0.16 earnings per share (EPS) in the quarter. The company had revenue of $ 42.07 million in the quarter. Global Cord Blood had a return on equity of 12.77% and a net margin of 42.17%.
Separately, BidaskClub cut Global Cord Blood from a “hold” rating to a “sell” rating in a research report on Friday, December 18.
About umbilical cord blood
Global Cord Blood Corporation, together with its subsidiaries, provides cord blood storage and ancillary services in the People’s Republic of China. The company offers testing, processing and storage of cord blood under the guidance of subscribers; and tests, processes and stores umbilical cord blood, as well as providing correspondence services.
Read More: What is a stock portfolio tracker?
Want to see what other hedge funds are keeping CO? Visit HoldingsChannel.com to obtain the latest 13F files and privileged deals for Global Cord Blood Co. (NYSE: CO).
Receive umbilical cord blood news and assessments daily – Enter your email address below to receive a concise daily summary of the latest news and reviews from Global Cord Blood analysts and related companies FREE daily email newsletter from MarketBeat.com.